$DFLI
Dragonfly Energy Holdings Corp. Stock $dfli

$dfli Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224032322 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q4
Revenue	$12.72M	$13.21M
YoY Change	-19.94%	-31.47%
Cost Of Revenue	$9.850M	$10.04M
YoY Change	-12.96%	-33.84%
Gross Profit	$2.870M	$3.167M
YoY Change	-37.23%	-22.72%
Gross Profit Margin	22.56%	23.98%
Selling, General & Admin	$7.265M	$8.385M
YoY Change	-20.06%	-26.59%
% of Gross Profit	253.14%	264.76%
Research & Development	$1.631M	$1.531M
YoY Change	17.76%	43.49%
% of Gross Profit	56.83%	48.34%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$8.896M	$9.916M
YoY Change	-15.06%	-20.6%
Operating Profit	-$6.026M	-$6.749M
YoY Change	2.12%	-19.57%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$753.0K	-$6.878M
YoY Change	-81.73%	107.86%
Pretax Income	-$6.779M	-$13.63M
YoY Change	-32.37%	16.47%
Income Tax
% Of Pretax Income
Net Earnings	-$6.779M	-$13.63M
YoY Change	-32.37%	16.47%
Net Earnings / Revenue	-53.29%	-103.17%
Basic Earnings Per Share	-$0.11	-$0.22
Diluted Earnings Per Share	-$0.11	-$0.22
COMMON SHARES
Basic Shares Outstanding	62.59M shares	60.26M shares	59.55M shares
Diluted Shares Outstanding	62.33M shares	60.67M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$8.019M	$4.699M	$12.71M
Short-Term Investments
Other Short-Term Assets	$753.0K	$750.0K	$118.0K
YoY Change	538.14%	213.81%	-55.81%
Inventory	$24.01M	$28.65M	$38.78M
Prepaid Expenses
Receivables	$3.727M	$2.866M	$1.639M
Other Receivables
Total Short-Term Assets	$39.34M	$40.07M	$55.92M
YoY Change	-37.58%	-52.43%	-23.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.72M	$23.50M	$15.97M
YoY Change	49.38%	48.83%	48.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$445.0K	$445.0K
YoY Change
Total Long-Term Assets	$44.54M	$44.89M	$19.28M
YoY Change	128.54%	127.88%	26.26%
TOTAL ASSETS
Total Short-Term Assets	$39.34M	$40.07M	$55.92M
Total Long-Term Assets	$44.54M	$44.89M	$19.28M
Total Assets	$83.88M	$84.96M	$75.20M
YoY Change	1.66%	-18.26%	-15.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.13M	$10.34M	$10.26M
YoY Change	2.42%	-48.28%	-23.87%
Accrued Expenses
YoY Change
Deferred Revenue	$189.0K	$250.0K	$201.0K
YoY Change	-12.9%	64.47%	-15.55%
Short-Term Debt
YoY Change
Long-Term Debt Due	$24.40M	$21.90M	$19.68M
YoY Change	30.47%	-2.1%	2.29%
Total Short-Term Liabilities	$49.26M	$44.65M	$40.38M
YoY Change	20.09%	-16.76%	-0.47%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$34.91M	$35.04M	$6.915M
YoY Change	103.51%	93.83%	-81.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$49.26M	$44.65M	$40.38M
Total Long-Term Liabilities	$34.91M	$35.04M	$6.915M
Total Liabilities	$84.18M	$79.69M	$47.29M
YoY Change	44.69%	11.12%	-38.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$72.31M	-$65.53M	-$41.54M
YoY Change	64.48%	93.08%	53.09%
Common Stock	$6.000K	$6.000K	$6.000K
YoY Change	0.0%	0.0%	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$297.0K	$5.266M	$27.91M
YoY Change
Total Liabilities & Shareholders Equity	$83.88M	$84.96M	$75.20M
YoY Change	1.66%	-18.26%	-15.27%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$6.779M	-$13.63M
YoY Change	-32.37%	16.47%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8565000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12588000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001847986
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	DFLI	Uncertain Tax Position Liability UncertainTaxPositionLiability	91000	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	21903000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2807000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	37000	usd
CY2024Q2	DFLI	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	11004000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23990000	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	46000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	35040000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	79689000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	70793000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65533000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	5266000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	84955000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13208000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	DFLI	Stock Issued During Period Value Vested Restricted Stock Units StockIssuedDuringPeriodValueVestedRestrictedStockUnits		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2024Q2	DFLI	Stock Issued During Period Value Vested Restricted Stock Units StockIssuedDuringPeriodValueVestedRestrictedStockUnits		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	DFLI	Recognition Of Leasehold Improvements Obtained In Exchange For Operating Lease Liability RecognitionOfLeaseholdImprovementsObtainedInExchangeForOperatingLeaseLiability		usd
	DFLI	Recognition Of Warrant Liability RecognitionOfWarrantLiability		usd
	DFLI	Settlement Of Accrued Liability For Employee Stock Purchase Plan SettlementOfAccruedLiabilityForEmployeeStockPurchasePlan		usd
	DFLI	Cashless Exercise Of Liability Classified Warrants CashlessExerciseOfLiabilityClassifiedWarrants		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
	DFLI	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber		shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40730
	dei	Entity Registrant Name EntityRegistrantName	DRAGONFLY ENERGY HOLDINGS CORP.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1873463
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1190 Trademark Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	#108
CY2023Q4	DFLI	Uncertain Tax Position Liability UncertainTaxPositionLiability	91000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	19683000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1288000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	44649000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40377000	usd
CY2023Q4	DFLI	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	4463000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	152000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2234000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	66000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6915000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	47292000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61367633	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61367633	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60260282	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60260282	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69445000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41539000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	27912000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	75204000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19274000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25713000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38065000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10041000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15350000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19495000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29474000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	3167000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	3924000	usd
	us-gaap	Gross Profit GrossProfit	6218000	usd
	us-gaap	Gross Profit GrossProfit	8591000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1531000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1067000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2864000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1947000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5704000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7614000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10517000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17109000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2681000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3808000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5425000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7992000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	9916000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	12489000	usd
	us-gaap	Operating Expenses OperatingExpenses	18806000	usd
	us-gaap	Operating Expenses OperatingExpenses	27048000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6749000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18457000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4878000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4138000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	9638000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	7994000	usd
CY2024Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	19000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23000	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1981000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-804000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1745000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19327000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6878000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3334000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11406000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11333000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13627000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11899000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23994000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7124000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-13627000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11899000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23994000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7124000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60673835	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60673835	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47418269	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47418269	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10743000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4775000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	597000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	93000	usd
CY2023Q1	DFLI	Stock Issued During Period Value Exercise Of Public Warrants StockIssuedDuringPeriodValueExerciseOfPublicWarrants	747000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10167000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4487000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	31609000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11899000	usd
CY2023Q2	DFLI	Stock Issued During Period Value Public Offering StockIssuedDuringPeriodValuePublicOffering	7878000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	74000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	230000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2462000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	954000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	31308000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	27912000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10367000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	266000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	17811000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	17811000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-13627000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-13627000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	730000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	112000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	237000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	5266000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	5266000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23994000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7124000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	503000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5441000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2428000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	620000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1745000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19327000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	4582000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	2510000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	18000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	93000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	663000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	593000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1019000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	601000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-116000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1246000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	821000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10125000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5648000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-425000	usd
	DFLI	Increase Decrease In Prepaid Inventory IncreaseDecreaseInPrepaidInventory	595000	usd
	DFLI	Increase Decrease In Prepaid Inventory IncreaseDecreaseInPrepaidInventory	940000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	632000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-28000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	445000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	174000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-4000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1970000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6272000	usd
	DFLI	Increase Decrease In Accrued Tariff IncreaseDecreaseInAccruedTariff	150000	usd
	DFLI	Increase Decrease In Accrued Tariff IncreaseDecreaseInAccruedTariff	316000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	49000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-86000	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	16564000	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1485000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7430000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5639000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1324000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2571000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1324000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2571000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	788000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	23527000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	51000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1216000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2700000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2700000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1000000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	747000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	323000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	740000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23381000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8014000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	15171000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12713000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17781000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4699000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32952000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	237000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4780000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4361000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2278000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3583000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18653000	usd
	DFLI	Recognition Of Leasehold Improvements Obtained In Exchange For Operating Lease Liability RecognitionOfLeaseholdImprovementsObtainedInExchangeForOperatingLeaseLiability	4683000	usd
	DFLI	Recognition Of Warrant Liability RecognitionOfWarrantLiability	4796000	usd
	DFLI	Settlement Of Accrued Liability For Employee Stock Purchase Plan SettlementOfAccruedLiabilityForEmployeeStockPurchasePlan	112000	usd
	DFLI	Cashless Exercise Of Liability Classified Warrants CashlessExerciseOfLiabilityClassifiedWarrants	12628000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80E_eus-gaap--NatureOfOperations_z1hq2A0aeTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif; text-transform: uppercase"><b>Note 1 - <span id="xdx_820_zztw6i95Ytyc">NATURE OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dragonfly Energy Holdings Corp. (“New Dragonfly” or the “Company”) sells lithium-ion battery packs for use in a wide variety of applications. The Company sells to distributors under the Dragonfly Energy brand name, and sells direct to consumers under the trade name Battleborn Batteries. In addition, the Company develops technology for improved lithium-ion battery manufacturing and assembly methods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Cash Cash	4699000	usd
	DFLI	Working Capital WorkingCapital	4584000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zcxcGPV5VLy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company utilizes the use of estimates in its calculations for the reserve for obsolete or slow-moving inventory, right of use asset, warrant liability, equity-based compensation, and income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	250000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	201000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	153000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	153000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	211000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	211000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13208000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19274000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25713000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38065000	usd
CY2024Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	467000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	307000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	307000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	328000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	319000	usd
CY2023	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	397000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	159000	usd
CY2023	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	418000	usd
CY2024Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	467000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	307000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zLmgPUVA0Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, receivables from Customer A and Customer B comprised approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zZq6NTzocSSj" title="Concentration risk, percentage">21</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zDQZPJROZhka" title="Concentration risk, percentage">17</span>%, respectively, of accounts receivable. As of December 31, 2023, receivables from Customer A and C comprised approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zSbMj1JfA6g6" title="Concentration risk, percentage">28</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zlI8rjb1DBb3" title="Concentration risk, percentage">10</span>%, respectively, of accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2024, sales from Customer A comprised approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zQTTOD9VhLA9" title="Concentration risk, percentage">14</span>% of the Company’s total revenue. For the six months ended June 30, 2023, sales from Customer B accounted for approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zuKUYJf3vUA5" title="Concentration risk, percentage">26</span>% of the Company’s total revenue. For the three months ended June 30, 2024, sales from Customer A comprised approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240401__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zib8vgFjNJZk" title="Concentration risk, percentage">12</span>% of the Company’s total revenue. For the three months ended June 30, 2023, sales from Customer B accounted for approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zI5xHUcjttIa" title="Concentration risk, percentage">27</span>% of the Company’s total revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, payables to Vendor A and Vendor B comprised approximately <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorAMember_zkOufNgFXSC1" title="Concentration risk, percentage">39</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorBMember_zPdYyjiCYjX8" title="Concentration risk, percentage">13</span>%, respectively, of accounts payables. As of December 31, 2023, payables to Vendor A comprised approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorAMember_zJnzjabKsma2" title="Concentration risk, percentage">65</span>% of accounts payables.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2024, there were <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dpo_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorMember_ztXtoRXVzKQ6" title="Concentration risk, percentage">no</span> purchase concentrations present. For the six months ended June 30, 2023, Vendor A accounted for approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorAMember_z9oXLeoNANW8" title="Concentration risk, percentage">22</span>% of the Company’s total purchases. For the three months ended June 30, 2024, Vendor B accounted for approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240401__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorBMember_z7d0BCkaIEgk" title="Concentration risk, percentage">15</span>% of the Company’s total purchases. For the three months ended June 30, 2023, Vendor C accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorCMember_zMtmL4vnuOcd" title="Concentration risk, percentage">10</span>% of the Company’s total purchases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	91000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	91000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31183072000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27143320000	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4jk3vFswUP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation in the condensed consolidated financial statements and these accompanying notes. The reclassifications did not have a material impact on the Company’s unaudited condensed consolidated financial statements and related disclosures. The impact on any prior period disclosures was immaterial.</span></p>
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	23192000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	31604000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5461000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7174000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	28653000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	38778000	usd
CY2022Q1	DFLI	Lessee Operating Lease Monthly Base Rent LesseeOperatingLeaseMonthlyBaseRent	230000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	23000	usd
CY2022Q1	DFLI	Lessee Operating Lease Estimated Monthly Property Taxes LesseeOperatingLeaseEstimatedMonthlyPropertyTaxes	21000	usd
CY2022Q1	DFLI	Lessee Operating Lease Percentage Of Escalation Of Monthly Base Rent LesseeOperatingLeasePercentageOfEscalationOfMonthlyBaseRent	0.03	pure
CY2022Q1	DFLI	Lessee Operating Lease Percentage Of Escalation Of Fix Operating Expense Costs LesseeOperatingLeasePercentageOfEscalationOfFixOperatingExpenseCosts	0.024	pure
CY2024Q2	us-gaap	Area Of Land AreaOfLand	64000	sqft
CY2024Q2	us-gaap	Payments For Rent PaymentsForRent	45000	usd
CY2024Q2	DFLI	Lease Term Percentage LeaseTermPercentage	0.030	pure
CY2024Q2	us-gaap	Security Deposit SecurityDeposit	50000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20949000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3315000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2807000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1288000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23990000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2234000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	26797000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3522000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y9M10D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0782	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2371000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4817000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4376000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3588000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3695000	usd
CY2024Q2	DFLI	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	19221000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	38068000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11271000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	26797000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1244000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	395000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1899000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	788000	usd
CY2024Q2	DFLI	Finance Lease Right Of Use Assets FinanceLeaseRightOfUseAssets	94000	usd
CY2023Q4	DFLI	Finance Lease Right Of Use Assets FinanceLeaseRightOfUseAssets	106000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	37000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	46000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	66000	usd
CY2024Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	83000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	102000	usd
CY2024Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2024Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2024Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	20000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	41000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	24000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	4000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	89000	usd
CY2024Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	6000	usd
CY2024Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	83000	usd
CY2024Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	30846000	usd
CY2024Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.140	pure
CY2024Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.140	pure
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3022	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1767	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	938000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	80419000	usd
CY2024Q2	DFLI	Long Term Debt Maturities Repayments Of Principal LongTermDebtMaturitiesRepaymentsOfPrincipal	81357000	usd
CY2024Q2	DFLI	Estimated Interest Paidinkind EstimatedInterestPaidinkind	-921000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	80436000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	58533000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	21903000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	21903000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3000000	usd
	DFLI	Stock Issued During Period Shares Exercise Of Public Warrants StockIssuedDuringPeriodSharesExerciseOfPublicWarrants	0	shares
	DFLI	Class Of Warrant Or Right Exercisable To Purchase Description ClassOfWarrantOrRightExercisableToPurchaseDescription	the Company issued (i) the penny warrants to the Term Loan Lenders exercisable to purchase an aggregate of 2,593,056 shares of Common Stock (the “Original Penny Warrants”) and (ii) the $10 warrants to issue warrants to the Term Loan Lenders exercisable to purchase an aggregate of 1,600,000 shares of Common Stock at $10 per share (the “$10 Warrants” and, together with the Original Penny Warrants, the “Term Loan Warrants”). The $10 Warrants were exercised on a cashless basis on October 10, 2022, with the Company issuing 457,142 shares of Common Stock in connection with such exercise.
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1908821	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3443099	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61367633	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58504541	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	29168251	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	23492221	shares
CY2024Q2	DFLI	Earnout Shares EarnoutShares	25000000	shares
CY2023Q2	DFLI	Earnout Shares EarnoutShares	40000000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	8957130	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4434916	shares
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	126401835	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	129874777	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	503000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5441000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	237000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	954000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	503000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5441000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	237000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	954000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2364787	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.69
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.57
CY2023	DFLI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P7Y7M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	60000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	218488	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.94
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	1.62
	DFLI	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod	228726	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.88
	DFLI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Expired Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue	1.68
	DFLI	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue	1000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8752	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.35
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.52
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1908821	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.64
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.55
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M17D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	182000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1536895
	DFLI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Vested And Exercisable Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsVestedAndExercisableWeightedAverageGrantDateFairValue	2.45
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y4M17D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	179000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1908821
	DFLI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Vested And Expected Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsVestedAndExpectedWeightedAverageGrantDateFairValue	2.64
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y7M17D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	182000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8752	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3	usd
CY2024Q2	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	3428	shares
CY2024Q2	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	375	shares
CY2024Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	244774	shares
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	112	usd
CY2024Q2	DFLI	Employee Purchase Shares Percentage EmployeePurchaseSharesPercentage	0.15	pure
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15350000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	3924000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8565000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	4138000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11899000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11899000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29474000	usd
	us-gaap	Gross Profit GrossProfit	8591000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18457000	usd
	us-gaap	Interest Expense InterestExpense	-7994000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7124000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7124000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
	us-gaap	Net Income Loss NetIncomeLoss	-7124000	usd
	DFLI	Increase Decrease In Accrued Tariffs IncreaseDecreaseInAccruedTariffs	316000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27722000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4775000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22947000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22947000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11899000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11899000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34846000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34846000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-032322-index-headers.html	Edgar Link	pending
0001493152-24-032322-index.html	Edgar Link	pending
0001493152-24-032322.txt	Edgar Link	pending
0001493152-24-032322-xbrl.zip	Edgar Link	pending
dfli-20240630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
dfli-20240630_cal.xml	Edgar Link	unprocessable
dfli-20240630_def.xml	Edgar Link	unprocessable
dfli-20240630_lab.xml	Edgar Link	unprocessable
dfli-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DFLI
Dragonfly Energy Holdings Corp. Stock $dfli

2024 Q3 Form 10-Q Financial Statement

#000149315224032322 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFLI Dragonfly Energy Holdings Corp. Stock $dfli

2024 Q3 Form 10-Q Financial Statement

#000149315224032322 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFLI
Dragonfly Energy Holdings Corp. Stock $dfli